Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOS phase II neoadjuvant paclitaxel + carboplatin in operable locally advanced head and neck squamous cell carcinoma
KCT0007197Phase 2Completed
- Sponsor
- Boryung
- Start
- Jan 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Boryung. Primary endpoint: Major pathologic response. Started Jan 2023; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on KCT0007197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007197.